RXRX Key Statistics, Chart & Performance
The current stock price of RXRX is 3.98 USD. In the past month the price decreased by -15.32%. In the past year, price decreased by -46.86%.
RXRX Technical Analysis
RXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RXRX. RXRX has a bad profitability rating. Also its financial health evaluation is rather negative.
RXRX Financial Highlights
Over the last trailing twelve months RXRX reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -16.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.13% | ||
| ROE | -68.35% | ||
| Debt/Equity | 0.01 |
RXRX Forecast & Estimates
14 analysts have analysed RXRX and the average price target is 7.14 USD. This implies a price increase of 79.4% is expected in the next year compared to the current price of 3.98.
For the next year, analysts expect an EPS growth of 1.61% and a revenue growth -12.97% for RXRX
RXRX Ownership
RXRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.886B | ||
| AMGN | AMGEN INC | 16.68 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.74 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.62 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RXRX
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 840 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Company Info
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101 US
CEO: Christopher Gibson
Employees: 840
Phone: 13026744089
RECURSION PHARMACEUTICALS-A / RXRX FAQ
What does RECURSION PHARMACEUTICALS-A do?
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 840 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
What is the current price of RXRX stock?
The current stock price of RXRX is 3.98 USD.
What is the dividend status of RECURSION PHARMACEUTICALS-A?
RXRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of RXRX stock?
RXRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy RXRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RXRX.
What is the market capitalization of RXRX stock?
RECURSION PHARMACEUTICALS-A (RXRX) has a market capitalization of 2.07B USD. This makes RXRX a Mid Cap stock.
Who owns RECURSION PHARMACEUTICALS-A?
You can find the ownership structure of RECURSION PHARMACEUTICALS-A (RXRX) on the Ownership tab.